Literature DB >> 25810578

Severe skin toxicity due to weekly paclitaxel administration.

Shruti Kate1, Seema Gulia1, Sudeep Gupta1.   

Abstract

Entities:  

Year:  2015        PMID: 25810578      PMCID: PMC4363854          DOI: 10.4103/0971-5851.151795

Source DB:  PubMed          Journal:  Indian J Med Paediatr Oncol        ISSN: 0971-5851


× No keyword cloud information.
A 35-year-old lady was diagnosed with a left-sided breast cancer (infiltrating ductal carcinoma, grade 2, estrogen receptor/progesterone receptor positive, human epidermal growth factor receptor 2 negative). She received neoadjuvant anthracycline-based chemotherapy, followed by breast conserving surgery. Postoperatively she commenced weekly paclitaxel 80 mg/m2/week. After the 8th dose, she presented with painful swelling of hands, feet and a bilateral symmetrical rash over the extensor surfaces of legs up to the knees-ill-defined macules, papules and pustules with surrounding erythema [Figures 1a and b]. She improved with a 5-day course of low dose oral prednisolone and an oral antibiotic. Chemotherapy was terminated and she was started on adjuvant tamoxifen.
Figure 1a

Severe skin toxicity due to weekly paclitaxel-bilaterally symmetrical rash over the extensor surfaces of legs up to knees comprising of ill-defined macules, papules and pustules with surrounding erythema

Figure 1b

Swelling of the hands with ill-defined macules and papules with diffuse erythema

Severe skin toxicity due to weekly paclitaxel-bilaterally symmetrical rash over the extensor surfaces of legs up to knees comprising of ill-defined macules, papules and pustules with surrounding erythema Swelling of the hands with ill-defined macules and papules with diffuse erythema
  1 in total

1.  Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model.

Authors:  Paula Montero; Javier Milara; Martín Pérez-Leal; Cristina Estornut; Inés Roger; Alejandro Pérez-Fidalgo; Celia Sanz; Julio Cortijo
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.